Telomir Pharmaceuticals Reveals Promising Vision Restoration in Preclinical AMD Study
Telomir Pharmaceuticals has demonstrated its oral therapeutic candidate Telomir-1 can restore vision and reverse retinal degeneration in a zebrafish model of age-related macular degeneration, highlighting potential breakthrough treatment for vision loss.
Telomir Pharmaceuticals has reported significant preclinical results for its oral therapeutic candidate Telomir-1, showing potential to restore vision and regenerate retinal tissue in a zebrafish model of age-related macular degeneration (AMD).
In a 14-day study, the experimental treatment demonstrated remarkable capabilities, including improving central vision response and restoring retinal architecture across multiple critical layers. The research revealed that Telomir-1 reduced oxidative stress by up to 50% and eliminated mortality observed in untreated animals.
The zebrafish treated with Telomir-1 exhibited full recovery of visual function and structural regeneration, particularly in the inner nuclear and ganglion cell layers. These findings suggest the potential for a regenerative approach to treating AMD, a condition that currently lacks comprehensive treatment options.
This research represents a critical step in Telomir Pharmaceuticals' broader mission to develop treatments that address age-related cellular degradation. By targeting telomere protection and potential regeneration, the company aims to develop interventions that could significantly impact age-related degenerative diseases.
The preclinical study provides early evidence of Telomir-1's potential to not just slow vision loss, but potentially reverse existing damage, which could represent a paradigm shift in treating AMD and potentially other degenerative conditions.